Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Empagliflozin/Linagliptin FDC Bioavailability in Healthy Japanese Men
NCT02815644Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma for Linagliptin at 72 hours, Maximum measured concentration of the analyte in plasma for Empagliflozin at 72 hours and 2 more. Started Jul 2016; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02815644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815644.